Print This Page

Sign Up for Fundamentals

Stay up-to-date with the latest research findings from the Institute for Basic Biomedical Sciences.

Fundamentals Topics+

Fundamentals

Drug's Approval Marks a Milestone in Personalized Cancer Treatment

The FDA approval of a drug targeting tumors based on genetics rather than type marked a milestone in precision medicine. Research at Johns Hopkins and elsewhere suggests the drug can help 1 in 25 advanced cancer patients who would otherwise have little hope of treatment.

Read more

Watch This

More Videos

Blocking Rogue Genes

Philip Cole discusses how his research group is synthesizing new molecules that can block the action of disease-causing genes. Their research can help in developing new cancer treatments.

Dung Le on the Hard Work Behind a Historic Drug Approval

Dung Le is an associate professor of oncology at the Johns Hopkins University School of Medicine and member of the Johns Hopkins Bloomberg~Kimmel Institute. She co-led a clinical trial that was instrumental in the Food and Drug Administration’s recent approval of the drug pembrolizumab to treat cancers based on their genetic characteristics.

Read full interview

Highlights

Reversing the Loss of Sight

A novel peptide and drug delivery system puts researchers closer to improving vision care for millions who suffer from degenerative retinal diseases.

Learn more.

Nanoparticles May Improve Effectiveness of Cancer Immunotherapies

Scientists created a nanoparticle capable of simultaneously switching off cancer cells’ defensive properties while switching on a robust anticancer immune response

Learn more.

Reservoirs of Latent HIV Can Grow Despite Effective Therapy

Although HIV can be controlled with therapy in most cases, the proliferation of such reservoirs pose a barrier to developing a cure for HIV.

Learn more.

New Cellular Target May Halt Cancer's Ability to Spread

Researchers discovered a biochemical signaling process that causes cancer cells to break away from a tumor and spread the disease in the body.

Read more.

Flaws in Genetic Mending Kit of Cancer Drives Response to Immunotherapy

Results from a three-year clinical trial found that half of the patients respond to an immunotherapy drug called pembrolizuma. 

Read more.